{"id":"W4388694835","doi":"10.1016/j.jhep.2023.10.040","title":"Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours","year":2023,"lang":"en","type":"article","venue":"Journal of Hepatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"National Institute on Minority Health and Health Disparities; Genentech; Bayer HealthCare; G1 Therapeutics; MacroGenics; Tarveda Therapeutics; Pfizer; Incyte; Mersana Therapeutics; Les Laboratories Pierre Fabre; Ipsen; Jazz Pharmaceuticals; ViiV Healthcare; Agios Pharmaceuticals; Sirtex Medical; Cancer Research UK; Wellcome Trust; Exelixis; Revolution Medicines; Regeneron Pharmaceuticals; Astellas Pharma; Eisai; FibroGen; Servier; Gilead Sciences; Sanofi; GlaxoSmithKline; OncoMed Pharmaceutical; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Falk Foundation","keywords":"Medicine; Internal medicine; Hepatocellular carcinoma; Gastroenterology; Incidence (geometry); Bevacizumab; Atezolizumab; Cohort; Cumulative incidence; Liver cancer; Cancer; Immunotherapy; Oncology; Nivolumab; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002336889,0.0001518551,0.000676052,0.0003626485,0.00002363112,0.000004266954,0.0000850609,0.0001154295,0.00007044589],"category_scores_gemma":[0.00004126817,0.0001084968,0.0001021352,0.0002752158,0.0001546716,0.00007685703,0.00002528414,0.0002188248,0.000002838508],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007501187,"about_ca_system_score_gemma":0.0001231159,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005604325,"about_ca_topic_score_gemma":0.000008945915,"domain_scores_codex":[0.9987506,0.00006924992,0.0006336987,0.0001221558,0.0002097044,0.0002145863],"domain_scores_gemma":[0.999034,0.00008604338,0.0005120838,0.0001519054,0.0001588995,0.00005700129],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02018633,0.000166944,0.967015,0.00003557915,0.0003084427,0.0001184318,0.0003816681,5.778016e-7,0.00295064,0.00000625659,0.0000494997,0.008780622],"study_design_scores_gemma":[0.01424527,0.002702418,0.9805577,0.0001135876,0.00007638583,0.0000429956,0.00006519462,0.00008486037,0.001670233,0.00001284105,0.0003202915,0.000108209],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9984202,0.0006602345,0.000003283043,0.0002726101,0.0003879934,0.0001977267,0.00001349457,0.000009816135,0.00003464691],"genre_scores_gemma":[0.9990352,0.0006078494,0.0001041309,0.0001552115,0.00001572722,0.000002595822,0.000006690652,0.00002736236,0.0000452386],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0135427,"threshold_uncertainty_score":0.442437,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01122029119293104,"score_gpt":0.2627151369099966,"score_spread":0.2514948457170655,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}